{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:43:27Z","timestamp":1779335007793,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, small vessel, necrotizing vasculitis. The disease is mainly characterized by hypereosinophilia and asthma with frequent sinonasal involvement, although multiple organs can be affected, including the heart, lungs, skin, gastrointestinal tract, kidneys, and nervous system. IL-5 production is pathogenetically central for the development of the disease by promoting proliferation, transvascular migration and functional activation of eosinophils. The degree of blood and tissue eosinophilia appears to be associated with disease pathogenesis and eosinophil depletion represents a promising treatment approach for EGPA. We prospectively evaluated the efficacy and safety of a low dose (100\u00a0mg q4w), 12-month course of mepolizumab, an anti-IL-5 monoclonal antibody, in eight patients with severe asthma and active EGPA. Patients were recruited by the tertiary care center of Clinical Immunology and Allergy, University of Naples Federico II. The following outcomes were assessed before (T0), and after 6 (T6) and 12\u00a0months (T12) of mepolizumab treatment: Birmingham Vasculitis Activity Score (BVAS), prednisone intake, Sino-Nasal Outcome Test (SNOT-22), Total Endoscopic Polyp Score (TENPS), Asthma Control Test (ACT), Forced Expiratory Volume one second (FEV1)%, blood eosinophilia. BVAS score significantly decreased showing a sharp reduction in disease activity score. Clinical improvements in terms of sinonasal scores and asthma symptoms were observed, in parallel with a drastic drop in eosinophil blood count. Prednisone intake was significantly reduced. In two patients, asthma exacerbations led to discontinuation in mepolizumab therapy after 6 and 12\u00a0months despite BVAS reduction. Mepolizumab treatment was well tolerated, and no severe adverse drug effects were registered. In conclusion, our 12-month real-life study suggests that mepolizumab may be beneficial and safe in active EGPA patients by improving disease activity score, sinonasal and asthma outcomes while reducing the burden of prednisone intake.<\/jats:p>","DOI":"10.1186\/s12931-021-01775-z","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:04:21Z","timestamp":1624435461000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3692-1384","authenticated-orcid":false,"given":"Aikaterini","family":"Detoraki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Tremante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remo","family":"Poto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Quaremba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francescopaolo","family":"Granata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Mormile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca Wanda","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amato","family":"de Paulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"1775_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/art.20077","volume":"51","author":"A Mahr","year":"2004","unstructured":"Mahr A, Guillevin L, Poissonnet M, Ayme S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener\u2019s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004;51:92\u20139.","journal-title":"Arthritis Rheum"},{"key":"1775_CR2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/BF01450893","volume":"17","author":"G Haugeberg","year":"1998","unstructured":"Haugeberg G, Bie R, Bendvold A, Larsen AS, Johnsen V. Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol. 1998;17:364\u20138.","journal-title":"Clin Rheumatol"},{"key":"1775_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s11926-005-0036-5","volume":"7","author":"SE Lane","year":"2005","unstructured":"Lane SE, Watts R, Scott DG. Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 2005;7:270\u20135.","journal-title":"Curr Rheumatol Rep"},{"key":"1775_CR4","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/pds.1353","volume":"16","author":"LR Harrold","year":"2007","unstructured":"Harrold LR, Patterson MK, Andrade SE, Dube T, Go AS, Buist AS, et al. Asthma drug use and the development of Churg-Strauss syndrome (CSS). Pharmacoepidemiol Drug Saf. 2007;16:620\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1775_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/(SICI)1099-1557(199905\/06)8:3<179::AID-PDS414>3.0.CO;2-K","volume":"8","author":"RM Martin","year":"1999","unstructured":"Martin RM, Wilton LV, Mann RD. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiol Drug Saf. 1999;8:179\u201389.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 1","key":"1775_CR6","doi-asserted-by":"publisher","first-page":"i14","DOI":"10.1093\/ndt\/gfv022","volume":"30","author":"RA Watts","year":"2015","unstructured":"Watts RA, Mahr A, Mohammad AJ, Gatenby P, Basu N, Flores-Suarez LF. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015;30(Suppl 1):i14-22.","journal-title":"Nephrol Dial Transplant"},{"key":"1775_CR7","doi-asserted-by":"crossref","unstructured":"Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine. 1999; 78:26\u201337.","DOI":"10.1097\/00005792-199901000-00003"},{"key":"1775_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/BOR.0b013e3280119854","volume":"19","author":"C Pagnoux","year":"2007","unstructured":"Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol. 2007;19:25\u201332.","journal-title":"Curr Opin Rheumatol"},{"key":"1775_CR9","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1586\/eci.09.41","volume":"5","author":"JU Holle","year":"2009","unstructured":"Holle JU, Moosig F, Gross WL. Diagnostic and therapeutic management of Churg-Strauss syndrome. Expert Rev Clin Immunol. 2009;5:813\u201323.","journal-title":"Expert Rev Clin Immunol"},{"key":"1775_CR10","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/art.21250","volume":"52","author":"RA Sinico","year":"2005","unstructured":"Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52:2926\u201335.","journal-title":"Arthritis Rheum"},{"key":"1775_CR11","first-page":"S41","volume":"32","author":"BM Sokolowska","year":"2014","unstructured":"Sokolowska BM, Szczeklik WK, Wludarczyk AA, Kuczia PP, Jakiela BA, Gasior JA, et al. ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single Polish center. Clin Exp Rheumatol. 2014;32:S41\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"1775_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1196\/annals.1361.053","volume":"1051","author":"B Hellmich","year":"2005","unstructured":"Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci. 2005;1051:121\u201331.","journal-title":"Ann N Y Acad Sci"},{"key":"1775_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","volume":"24","author":"ME Rothenberg","year":"2006","unstructured":"Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006;24:147\u201374.","journal-title":"Annu Rev Immunol"},{"key":"1775_CR14","first-page":"S69","volume":"21","author":"B Hellmich","year":"2003","unstructured":"Hellmich B, Ehlers S, Csernok E, Gross WL. Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol. 2003;21:S69-77.","journal-title":"Clin Exp Rheumatol"},{"key":"1775_CR15","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.4049\/jimmunol.164.7.3847","volume":"164","author":"S Shahabuddin","year":"2000","unstructured":"Shahabuddin S, Ponath P, Schleimer RP. Migration of eosinophils across endothelial cell monolayers: interactions among IL-5, endothelial-activating cytokines, and C\u2013C chemokines. J Immunol. 2000;164:3847\u201354.","journal-title":"J Immunol"},{"key":"1775_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.rdc.2010.05.003","volume":"36","author":"C Baldini","year":"2010","unstructured":"Baldini C, Talarico R, Della Rossa A, Bombardieri S. Clinical manifestations and treatment of Churg-Strauss syndrome. Rheum Dis Clin North Am. 2010;36:527\u201343.","journal-title":"Rheum Dis Clin North Am"},{"key":"1775_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3109\/02770903.2015.1081700","volume":"53","author":"A Detoraki","year":"2016","unstructured":"Detoraki A, Di Capua L, Varricchi G, Genovese A, Marone G, Spadaro G. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. J Asthma. 2016;53:201\u20136.","journal-title":"J Asthma"},{"key":"1775_CR18","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1002\/art.39663","volume":"68","author":"M Jachiet","year":"2016","unstructured":"Jachiet M, Samson M, Cottin V, Kahn JE, Le Guenno G, Bonniaud P, et al. Anti-IgE monoclonal antibody (Omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheumatol. 2016;68:2274\u201382.","journal-title":"Arthritis Rheumatol"},{"key":"1775_CR19","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376:1921\u201332.","journal-title":"N Engl J Med"},{"key":"1775_CR20","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198\u2013207.","journal-title":"N Engl J Med"},{"key":"1775_CR21","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/all.14048","volume":"75","author":"FC Albers","year":"2020","unstructured":"Albers FC, Hozawa S, Bratton DJ, Yancey SW, Prazma CM, Humbert M, et al. Update: mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use. Allergy. 2020;75:942\u20136.","journal-title":"Allergy"},{"key":"1775_CR22","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.2147\/TCRM.S159949","volume":"14","author":"P Faverio","year":"2018","unstructured":"Faverio P, Bonaiti G, Bini F, Vaghi A, Pesci A. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy. Ther Clin Risk Manag. 2018;14:2385\u201396.","journal-title":"Ther Clin Risk Manag"},{"key":"1775_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaci.2009.10.014","volume":"125","author":"JE Kahn","year":"2010","unstructured":"Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125:267\u201370.","journal-title":"J Allergy Clin Immunol"},{"key":"1775_CR24","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","volume":"125","author":"S Kim","year":"2010","unstructured":"Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125:1336\u201343.","journal-title":"J Allergy Clin Immunol"},{"key":"1775_CR25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/resp.13301","volume":"23","author":"G Thompson","year":"2018","unstructured":"Thompson G, Vasilevski N, Ryan M, Baltic S, Thompson P. Low-dose mepolizumab effectively treats chronic relapsing eosinophilic granulomatosis with polyangiitis. Respirology. 2018;23:178.","journal-title":"Respirology"},{"key":"1775_CR26","doi-asserted-by":"publisher","first-page":"885","DOI":"10.4168\/aair.2020.12.5.885","volume":"12","author":"A Vultaggio","year":"2020","unstructured":"Vultaggio A, Nencini F, Bormioli S, Vivarelli E, Dies L, Rossi O, et al. Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis. Allergy Asthma Immunol Res. 2020;12:885\u201393.","journal-title":"Allergy Asthma Immunol Res"},{"key":"1775_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.025","author":"M Caminati","year":"2020","unstructured":"Caminati M, Crisafulli E, Lunardi C, Micheletto C, Festi G, Maule M, et al. Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase. J Allergy Clin Immunol Pract. 2020. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.025.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1775_CR28","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/art.1780330806","volume":"33","author":"AT Masi","year":"1990","unstructured":"Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094\u2013100.","journal-title":"Arthritis Rheum"},{"key":"1775_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1\u201311.","journal-title":"Arthritis Rheum"},{"key":"1775_CR30","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827\u201332.","journal-title":"Ann Rheum Dis"},{"key":"1775_CR31","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.spinee.2007.01.008","volume":"7","author":"AG Copay","year":"2007","unstructured":"Copay AG, Subach BR, Glassman SD, Polly DW Jr, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J. 2007;7:541\u20136.","journal-title":"Spine J"},{"key":"1775_CR32","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/lary.25108","volume":"125","author":"L Rudmik","year":"2015","unstructured":"Rudmik L, Soler ZM, Mace JC, DeConde AS, Schlosser RJ, Smith TL. Using preoperative SNOT-22 score to inform patient decision for Endoscopic sinus surgery. Laryngoscope. 2015;125:1517\u201322.","journal-title":"Laryngoscope"},{"key":"1775_CR33","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","volume":"140","author":"C Bachert","year":"2017","unstructured":"Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. J Allergy Clin Immunol. 2017;140:1024\u201331.","journal-title":"J Allergy Clin Immunol."},{"key":"1775_CR34","doi-asserted-by":"crossref","unstructured":"Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019; 200:e70\u2013e88.","DOI":"10.1164\/rccm.201908-1590ST"},{"key":"1775_CR35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1183\/13993003.01046-2019","volume":"53","author":"HK Reddel","year":"2019","unstructured":"Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, et al. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53:78.","journal-title":"Eur Respir J."},{"key":"1775_CR36","doi-asserted-by":"crossref","unstructured":"Arlt W, Society for Endocrinology Clinical C. Society for endocrinology endocrine emergency guidance: Emergency management of acute adrenal insufficiency (adrenal crisis) in adult patients. Endocr Connect. 2016; 5:G1\u2013G3.","DOI":"10.1530\/EC-16-0054"},{"key":"1775_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/00016480500437435","volume":"126","author":"A Bacciu","year":"2006","unstructured":"Bacciu A, Bacciu S, Mercante G, Ingegnoli F, Grasselli C, Vaglio A, et al. Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol. 2006;126:503\u20139.","journal-title":"Acta Otolaryngol"},{"key":"1775_CR38","doi-asserted-by":"publisher","first-page":"175346662110093","DOI":"10.1177\/17534666211009398","volume":"15","author":"A Detoraki","year":"2021","unstructured":"Detoraki A, Tremante E, D\u2019Amato M, Calabrese C, Casella C, Maniscalco M, Poto R, Brancaccio R, Boccia M, Martino M, Imperatore C, Spadaro G. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study. Ther Adv Respir Dis 15:175346662110093","journal-title":"Ther Adv Respir Dis"},{"key":"1775_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.23822\/EurAnnACI.1764-1489.94","volume":"51","author":"M Kurosawa","year":"2019","unstructured":"Kurosawa M, Ogawa E, Sutoh E. Favorable clinical efficacy of mepolizumab on the upper and lower airways in severe eosinophilic asthma: a 48-week pilot study. Eur Ann Allergy Clin Immunol. 2019;51:213\u201321.","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"1775_CR40","first-page":"219","volume":"42","author":"MA Chobillon","year":"2004","unstructured":"Chobillon MA, Jankowski R. Relationship between mucoceles, nasal polyposis and nasalisation. Rhinology. 2004;42:219\u201324.","journal-title":"Rhinology"},{"key":"1775_CR41","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","volume":"155","author":"F Moosig","year":"2011","unstructured":"Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med. 2011;155:341\u20133.","journal-title":"Ann Intern Med"},{"key":"1775_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1183\/13993003.02345-2019","volume":"55","author":"C Taille","year":"2020","unstructured":"Taille C, Chanez P, Devouassoux G, Didier A, Pison C, Garcia G, et al. Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Eur Respir J. 2020;55:12.","journal-title":"Eur Respir J."},{"key":"1775_CR43","doi-asserted-by":"publisher","first-page":"101836","DOI":"10.1016\/j.pupt.2019.101836","volume":"58","author":"D Bagnasco","year":"2019","unstructured":"Bagnasco D, Caminati M, Menzella F, Milanese M, Rolla G, Lombardi C, et al. One year of mepolizumab. Efficacy and safety in real-life in Italy. Pulm Pharmacol Ther. 2019;58:101836.","journal-title":"Pulm Pharmacol Ther."},{"key":"1775_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13075-021-02462-6","volume":"23","author":"M Ueno","year":"2021","unstructured":"Ueno M, Miyagawa I, Nakano K, Iwata S, Hanami K, Fukuyo S, et al. Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis. Arthritis Res Ther. 2021;23:86.","journal-title":"Arthritis Res Ther"},{"key":"1775_CR45","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1183\/13993003.00963-2015","volume":"46","author":"M Groh","year":"2015","unstructured":"Groh M, Pagnoux C, Guillevin L. Eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): where are we now? Eur Respir J. 2015;46:1255\u20138.","journal-title":"Eur Respir J"},{"key":"1775_CR46","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2020.1827417:1-5","author":"M Vergles","year":"2020","unstructured":"Vergles M, Matkovic Z, Lalic K, Trkanjec JT, Tudoric N. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient? J Asthma. 2020. https:\/\/doi.org\/10.1080\/02770903.2020.1827417:1-5.","journal-title":"J Asthma"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-021-01775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-021-01775-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-021-01775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T07:11:40Z","timestamp":1675494700000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-021-01775-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1775"],"URL":"https:\/\/doi.org\/10.1186\/s12931-021-01775-z","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"assertion":[{"value":"28 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they respect standards of expected ethical behavior.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients signed informed consents for the publication of their data in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors report no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}